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ABSTRACT: Chronic obstructive pulmonary disease (COPD) often coexists with other chronic
diseases and comorbidities that can markedly influence patients’ health status and prognosis.
This is particularly true for cardiovascular disease (CVD). However, there have been no trials
assessing the effect of COPD medications on CVD in patients with both diseases.
The ‘‘Study to Understand Mortality and Morbidity in COPD’’ (SUMMIT) aims at determining the
impact of fluticasone furoate/vilanterol combination and the individual components on the
survival of patients with moderate COPD and either a history of CVD or at increased risk for CVD.
SUMMIT is a multicentre, randomised, double-blind, parallel-group, placebo-controlled trial of
16 000 patients with moderate COPD randomly assigned to once daily treatment with fluticasone
furoate/vilanterol (100/25 mg), fluticasone furoate (100 mg), vilanterol (25 mg) or matched placebo;
mortality is the primary end-point. The study is an event-driven trial powered by the comparison of
furoate/vilanterol versus placebo. Secondary end-points are decline in forced expiratory volume
in 1 s and effect on a composite cardiovascular end-point. This article describes the design of the
SUMMIT study.
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T
he morbidity and mortality of chronic
obstructive pulmonary disease (COPD)
continues to increase [1]. It is increasingly
recognised that COPD often coexists with other
chronic diseases and that comorbidities can con-
tribute to patients’ health status and prognosis
[2, 3]. Some of the changes seen in patients with
COPD have been termed extrapulmonary mani-
festations of COPD and typically include features
that are believed to be linked to progression of
COPD such as skeletal muscle dysfunction [4],
lean mass depletion [5], and osteoporosis and
osteopenia [6].
Other comorbidities are not so obviously linked to
disease progression and these include cardiovas-
cular disease (CVD). Several prospective studies
have reported an association between impaired
pulmonary function and cardiovascular morbidity
and mortality [7–10] even after adjusting for
accepted CVD risk factors. Epidemiological data
suggest that patients with COPD are at a greater
risk of CVD compared with age- and sex-matched
controls without COPD [11]. Furthermore, more
patients with mild-to-moderate COPD die from
lung cancer and CVDs, such as coronary artery
disease and stroke, than from the respiratory
effects of COPD [12–14]. Systemic inflammation
has been proposed as having a potential role in
explaining the association between COPD and
increased risk of CVD [15]. Other factors have also
been implicated, including autonomic imbalance,
vascular endothelial dysfunction, lower arterial
compliance and arrhythmias. It is, however, also
possible that the decreased physical activity
associated with even mild COPD [16] may increase
the risk of CVD, as well as other comorbidities.
The current Global Initiative for Obstructive
Lung Diseases (GOLD) strategy document has
highlighted the need to assess and treat comor-
bidities in COPD [1]. For most CVDs, the advice
is to treat the comorbidity as if the patient did not
have COPD and to treat COPD as in patients
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without CVD. However, the evidence base for treating COPD
patients with comorbidities is weak and most advice comes
from expert statements or from secondary analyses of large
studies. An example of the latter is the secondary analysis of
the TORCH (Towards a Revolution in COPD Health) study,
which focused on the safety of COPD medications in patients
with concomitant CVD entered into this large 3-year study
[17]. In addition to providing confidence in the safety of
treating these patients with salmeterol alone or in combination
with fluticasone propionate, the study also indicated that
treatment with combined salmeterol and fluticasone propio-
nate could have beneficial effects on the risk of cardiovascular
adverse events. Similarly, combination treatment seemed to
have a similar effect on respiratory and cardiovascular
mortality in the primary TORCH report [14]. Therefore, it
seems reasonable to hypothesise that combination treatment
may have a beneficial effect on survival in patients with COPD
and concomitant CVD.
The Study to Understand Mortality and Morbidity in COPD
(SUMMIT) is designed to prospectively compare the efficacy of
fluticasone furoate/vilanterol in combination (100/25 mg),
fluticasone furoate alone (100 mg) or vilanterol alone (25 mg)
against matched placebo once daily via the novel dry powder
inhaler on survival in subjects with moderate COPD and a
history of, or at increased risk for, CVD. The study will test the
hypothesis that treatment with combined inhaled corticoster-
oids (ICS) and long-acting b-agonists will reduce mortality
when compared with placebo. As most patients with severe or
very severe airflow limitation will require treatment with long-
acting bronchodilators and possibly ICS, and because comor-
bidities seem independent of severity of airflow limitation
[2–5], the study will include patients with moderate airflow
limitation only. This article describes the protocol design and
the approaches taken in this study that we anticipate will have
important implications for the future treatment of patients
with COPD.
METHODS
SUMMIT study design
This is an international, multicentre, placebo-controlled,
double-blind, randomised, parallel-group trial, with patients
expected to contribute 15–44 months of study time. The study
involves a 4–10 day run-in period, a treatment phase and a 1-
week follow-up phase. The length of the treatment phase will
depend on the mortality rate in the study; the study will last
until 1000 deaths have been recorded. All prior use of ICS and
inhaled long-acting bronchodilators will be discontinued at
entry to the run-in period. The population sought are those
patients with COPD that the practitioner believes can be
adequately managed without these medications. Patients will
be treated on an outpatient basis and clinic visits will occur at
screening, randomisation, 4 weeks, and then every 12 weeks
until the study has reached the required number of events.
Interventions
A total of 16 000 patients with moderate COPD and a history
of, or at increased risk for, CVD will be randomised from
,1100 sites to one of the following four treatment groups:
placebo; once-daily ICS fluticasone furoate (100 mg); once daily
inhaled b2-agonist vilanterol (25 mg); or fluticasone furoate/
vilanterol in combination (100/25 mg), administered once daily
via the novel dry powder inhaler. A separate randomisation
schedule will be produced for each country. Patients who
withdraw prematurely from study treatment will still be followed
up through regular contact until study termination to determine
survival status. The study is listed on ClinicalTrials.gov (www.
clinicaltrials.gov identifier NCT01313676).
Organisational committees
The study is being guided by a Steering Committee consisting of
external clinical experts and representatives of GlaxoSmithKline
(London, UK). An independent Safety and Efficacy Data
Monitoring Committee is overseeing the ethical and safety
interests of the patients by periodically reviewing results of
interim analyses and cumulative data on serious adverse events.
A Clinical End-point Committee is independently reviewing
and categorising the cause of death, as well as events that are
part of the cardiovascular composite end-point for each patient
where an event has been recorded.
Patient participation
Recruitment commenced in March 2011 and is expected to
conclude in late 2013. Patients are aged 40–80 years with a
smoking history of o10 pack-years, a clinical diagnosis of
COPD with forced expiratory volume in 1 s (FEV1)/forced
vital capacity ,0.70 and moderate airflow limitation, defined
as a post-albuterol/salbutamol FEV1 o50 and f70% of
predicted normal values, calculated using National Health
and Nutrition Examination Survey III reference equations
[18, 19]. In addition, patients are required to have a history of
CVD or to be at increased risk for CVD. The inclusion and most
important exclusion criteria are summarised in table 1.
Patients who have an exacerbation of COPD during the run-in
period that requires systemic corticosteroid therapy or
hospitalisation will not be eligible for randomisation. Patients
are allowed to take COPD medication except for ICS, long-
acting bronchodilators and long-term oral corticosteroids.
Tiotropium use will not be permitted at baseline. However, if
during the double-blind treatment phase, a subject experiences
a severe COPD exacerbation (i.e. requiring hospitalisation) and
requires additional treatment or experiences multiple moder-
ate exacerbations, tiotropium may be added. Tiotropium can
also be added by the investigator following a discussion with
the study medical monitor if the investigator believes the
addition is warranted to improve the management of the
subject’s disease. All patients will be offered salbutamol as
relief medication.
The study is conducted in accordance with the Declaration of
Helsinki and Good Clinical Practice Guidelines. All patients
will have given written informed consent before participating
in the study. Ethics and Review Boards of all participating
institutions have approved this protocol.
Efficacy and health outcome assessments
The primary end-point measure will be all-cause mortality.
Secondary end-points and other objectives are given in table 2.
An important secondary end-point is the cardiovascular
composite end-point comprising of on-treatment cardiovascu-
lar death, myocardial infarction, stroke, unstable angina and
transient ischaemic attack.
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Survival status
Survival status of each subject will be recorded at every visit. For
any subject who prematurely withdraws, survival status will be
captured at 3-monthly intervals by means of telephone calls or
other forms of contact. Accurate assignment of cause of death is
essential. The investigator will assign a cause of death based on
contact with the attending physician (where possible), details
given on the death certificate, autopsy findings (if any) and any
other available clinical evidence. Categorisation of cause of
death will also be performed centrally by a Clinical End-point
Committee who will review study data and any additional
information available (e.g. details given on the death certificate,
autopsy findings, and any other available clinical evidence).
The categorisation of cause of death assigned by the Clinical
End-point Committee will be the primary basis for all analyses
for specific cause of death. The Clinical End-point Committee
will build on decision rules developed in the TORCH study [20].
Clinical safety assessments
Each adverse event or concurrent illness during the study will
be documented on the case report form. For the purpose of this
study, a moderate COPD exacerbation is defined as an
exacerbation treated with antibiotics and/or systemic
corticosteroids whereas a severe COPD exacerbation required
hospitalisation. In this study, pneumonia is defined as new
auscultatory findings compatible with parenchymal lung
infection and/or radiographic evidence of parenchymal/air
space disease. A confirmed diagnosis of pneumonia must be
TABLE 1 Inclusion and exclusion criteria for the SUMMIT study
Key inclusion criteria
Male or female aged 40–80 years
Current or ex-smokers with a smoking history of o10 pack-years
An established history of COPD with an FEV1/FVC ratio ,0.70 and an FEV1 o50 and f70% of predicted normal
A history of CVD or to be at increased risk for CVD
For patients o40 years of age this is defined as any one of the following: established coronary artery disease, established peripheral vascular disease,
previous stroke, previous myocardial infarction or diabetes mellitus with target organ disease
For patients o60 years of age, any one of the above or two of the following: being treated for hypercholesterolaemia, being treated for hypertension, being
treated for diabetes mellitus or being treated for peripheral vascular disease
Key exclusion criteria
Current diagnosis of asthma or respiratory disorders other than COPD
Chest radiograph indicating diagnosis other than COPD
Undergone lung volume reduction surgery and/or a lung transplant
Requirement for long-term oxygen therapy at start of study (.12 h per day)
Receiving long-term oral corticosteroid therapy
Current severe heart failure (NYHA class IV), subjects will also be excluded if they have a known ejection fraction of ,30% or if they have an implantable
cardioverter defibrillator
Any life-threatening condition with life expectancy ,3 years, other than vascular disease or COPD, that might prevent the subject from completing the study
End-stage chronic renal disease
COPD: chronic obstructive pulmonary disease; SUMMIT: Study to Understand Mortality and Morbidity in COPD; FEV1: forced expiratory volume in 1 s; FVC: forced vital
capacity; CVD: cardiovascular disease; NYHA: New York Heart Association.
TABLE 2 Secondary end-points and other objectives in the SUMMIT study
Secondary end-points
To evaluate the effect of FF/VI compared with placebo on the rate of decline in FEV1
To evaluate the effect of FF/VI compared with placebo on a cardiovascular composite end-point comprised of on-treatment cardiovascular death, myocardial infarction,
stroke, unstable angina and TIA
Other objectives
To evaluate the following treatment comparisons on all primary, secondary, exploratory and other end-points: FF/VI compared with FF, FF/VI compared with VI, FF
compared with placebo, and VI compared with placebo
To evaluate the effect of FF/VI compared with placebo on the rate of moderate/severe COPD exacerbations
To evaluate the effect of FF/VI compared with placebo on COPD-related mortality
To evaluate the effect of FF/VI compared with placebo on arterial stiffness in a subset of subjects
To evaluate the effect of FF/VI compared with placebo on health-related quality of life measured with the SGRQ-C in a subset of subjects
To evaluate quality-adjusted life years by treatment group using health status data collected from EuroQol Questionnaire in a subset of subjects
To evaluate the impact of FF/VI compared with placebo on healthcare resource utilisation (measured by number of days hospitalised for COPD)
COPD: chronic obstructive pulmonary disease; SUMMIT: Study to Understand Mortality and Morbidity in COPD; FF: fluticasone furoate; VI: vilanterol; FEV1: forced
expiratory volume in 1 s; TIA: transient ischaemic attack; SGRQ-C: St George’s Respiratory Questionnaire for COPD.
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recorded as an adverse event. Patients with worsening COPD
status or progressive CVD while on study treatment can receive
other medications, or be withdrawn if in the investigator’s
opinion the patient’s deterioration prevents ongoing participa-
tion. The reason for withdrawal will be recorded and patients
will be followed up until study termination.
One formal interim analysis of the time to death from any cause
is planned in addition to the final analysis. It is intended that
this analysis will be performed when ,50% of the total deaths
have been observed. The analysis method for this will be the
same as that used in the final analysis, i.e. Cox proportional
hazards model.
Statistical analysis
This event driven study is designed to have 90% power to
detect a 30% reduction in the risk of all-cause mortality (hazard
ratio 0.70) on fluticasone furoate/vilanterol compared with
placebo at the two-sided 1% significance level. In order to
detect this reduction, 478 events (on fluticasone furoate/
vilanterol and placebo combined) would be required.
The effects of the components (fluticasone furoate and vilan-
terol) are expected to be lower than for fluticasone furoate/
vilanterol. The study is not powered for comparisons of the
components to placebo or for the combination to components. If
the true mortality rates for the components are intermediate
between fluticasone furoate/vilanterol and placebo, then it
would be expected that by the time there are 478 deaths between
the fluticasone furoate/vilanterol and placebo arms there
should be a roughly similar number on the component arms
combined, which would give a total of 956 on four arms.
However, since the study is blinded and it will be unknown
exactly how many deaths will have occurred on the fluticasone
furoate/vilanterol and placebo arms when it stops, a balance
must be struck between ensuring it runs long enough to accrue
478 deaths on those arms versus continuing the study for longer
than necessary. Therefore, a total number of 1000 deaths
(between four arms) will be used to trigger stopping of the
study for the final analysis.
The primary efficacy end-point of time to all-cause mortality
will be analysed using a Cox proportional hazards regression
model allowing for important pre-defined covariates that may
include, but not limited to, baseline FEV1, body mass index,
geographical region and smoking status.
DISCUSSION
COPD often coexists with other conditions, in particular CVD.
Importantly, the presence of one disease significantly affects
the prognosis of the other. In this context, there is a need for
evidence-based outcomes to support the efficacy of therapeutic
modalities for the treatment of patients with COPD with
concomitant CVD or its risk factors. As such, the SUMMIT trial
aims to evaluate the impact of inhaled COPD therapy in
patients with moderate COPD with, or at high risk for, CVD on
all-cause mortality.
COPD and CVD may coexist for a number of reasons. A list of
the most prominent mechanisms suggested is shown in table 3.
Smoking is clearly an important shared risk factor and physical
inactivity and deconditioning caused by COPD can clearly
contribute to the risk of CVD. However, there may also be
pathobiological links between the two diseases as a result of
systemic inflammation that is common to both diseases.
Inflammation in the small airways has been established as an
initial event in the pathogenesis of COPD [21, 22] and its
magnitude relates to the degree of airflow obstruction [22].
Recent studies suggest that the systemic inflammation seen in
some patients with COPD may promote the development of
atherosclerosis [23], the underlying cause of most ischaemic
heart disease. In addition, systemic inflammation related to
COPD (i.e. endothelial dysfunction) can produce structural
changes (e.g. elastin fragmentation and degeneration, and
increased collagen) and functional changes (e.g. reduced nitric
oxide) in the wall of the aorta and medium-sized arteries
resulting in decreased elasticity and increased stiffness [24].
Increased arterial stiffness is an independent predictor of
all-cause and cardiovascular morbidity and mortality in
hypertensive patients [25–27], as well as a predictor of
cardiovascular events in general populations [28, 29].
The extent to which these types of data apply to patients with
COPD is of increasing interest. ZUREIK et al. [30] demonstrated
that carotid-femoral pulse wave velocity (PWV) was negatively
associated with FEV1. Moreover, SABIT et al. [31] compared PWV
in COPD patients with healthy smokers and ex-smokers who
were free of cardiovascular disease and confirmed its negative
relationship to FEV1. In addition, by multiple regression
analysis, the circulating cytokine interleukin-6 was a strong
predictor of PWV in this study. The large ECLIPSE (Evaluation
of COPD Longitudinally to Identify Predictive Surrogate
Endpoints) cohort study of patients with COPD showed that
the presence of serum markers of inflammation increased the
capacity to predict mortality compared with validated clinical
predictors [32]. Increased PWV and elevated serum C-reactive
protein (CRP) have also been demonstrated in patients with
COPD compared with controls matched for age and smoking
history [33]. These latter findings may be important as CRP is
related to, and is a predictor of, cardiovascular risk [34]. Finally,
in a cross-sectional study, MCALLISTER et al. [35] demonstrated
that emphysema severity, as assessed by quantitative high-
resolution computerised tomography, is independently asso-
ciated with arterial stiffness. These observations raise the
potential of a possible link between the pulmonary and systemic
inflammation observed in COPD, with impaired larger artery
compliance as an important factor underlying the increased
cardiovascular morbidity and mortality that has been observed
TABLE 3 Potential mechanisms related to the presence
of cardiovascular disease in patients with chronic
obstructive pulmonary disease
Systemic inflammation
Physical inactivity and deconditioning
Autonomic imbalance
Vascular endothelial dysfunction
Lower arterial compliance
Arrhythmias
Thrombogenicity
Increased afterload resulting from a greater fall in pleural pressure at each
inspiration due to impaired lung mechanics in chronic obstructive pulmonary
disease
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in intervention studies [10, 14]. Carotid-femoral PWV will be
measured in a subset of patients in the SUMMIT trial at sites in
the USA and the UK.
ICS have not been shown to reduce mortality in COPD.
However, ICS do improve lung function and reduce exacer-
bations, both alone and in combination with a long-acting
b-agonist [36, 37]. It is possible that the reduction in
exacerbations in itself could result in a reduced risk of CVD
events. MCALLISTER et al. [38] recently showed that patients
admitted with a COPD exacerbation are likely to experience
ischaemic events during this episode. In the EUROSCOP
(European Respiratory Society Study on Chronic Obstructive
Pulmonary Disease) study, long-term treatment with budeso-
nide reduced ischaemic cardiac events in patients with mild
COPD [39] without significantly affecting the risk of severe
exacerbations. It is therefore likely that ICS in themselves may
have benefits in patients with comorbid CVD.
The SUMMIT trial contains a placebo arm and this requires
some consideration. All patients will be provided with a short-
acting bronchodilator for relief and this is accordance with
current COPD management strategies [1]. In addition,
although potentially important, none of the tested medication
classes in SUMMIT have been shown to provide long-term
benefits to patients with COPD and this is an important gap in
the evidence base. The SUMMIT trial is a long-term study
in COPD and it may be prone to some of the biases observed in
long-term trials in COPD resulting particularly from with-
drawal [40]. However, using an event-driven design may
reduce the risk of dilution bias. The study will use the same
strict trial review as in the TORCH study including intensive
follow-up and adjudication of deaths and CVD events. The
SUMMIT study will be one of the largest multicentre, long-
term COPD studies, and the first to investigate the effect of
inhaled medications in patients with COPD and concomitant
CVD. The data gathered may shed new light on the natural
history of both these disorders.
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